Recent years have witnessed remarkable progresses in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://jesseebjh071037.activosblog.com/37650399/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide